Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Telacebec for ultra-short treatment of Buruli ulcer in a mouse model.

Almeida DV, Converse PJ, Omansen TF, Tyagi S, Tasneen R, Kim J, Nuermberger EL.

Antimicrob Agents Chemother. 2020 Mar 23. pii: AAC.00259-20. doi: 10.1128/AAC.00259-20. [Epub ahead of print]

PMID:
32205344
2.

Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies.

Zhang N, Strydom N, Tyagi S, Soni H, Tasneen R, Nuermberger EL, Savic RM.

Antimicrob Agents Chemother. 2020 Feb 21;64(3). pii: e01727-19. doi: 10.1128/AAC.01727-19. Print 2020 Feb 21.

3.

Advancing the Therapeutic Potential of Indoleamides for Tuberculosis.

Lun S, Tasneen R, Chaira T, Stec J, Onajole OK, Yang TJ, Cooper CB, Mdluli K, Converse PJ, Nuermberger EL, Raj VS, Kozikowski A, Bishai WR.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00343-19. doi: 10.1128/AAC.00343-19. Print 2019 Jul.

4.

Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis.

Saini V, Ammerman NC, Chang YS, Tasneen R, Chaisson RE, Jain S, Nuermberger E, Grosset JH.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00388-19. doi: 10.1128/AAC.00388-19. Print 2019 Jun.

5.

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.

Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, Converse PJ, Upton AM, Mdluli K, Fotouhi N, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e00021-19. doi: 10.1128/AAC.00021-19. Print 2019 May.

6.

Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer.

Converse PJ, Almeida DV, Tasneen R, Saini V, Tyagi S, Ammerman NC, Li SY, Anders NM, Rudek MA, Grosset JH, Nuermberger EL.

PLoS Negl Trop Dis. 2018 Aug 13;12(8):e0006728. doi: 10.1371/journal.pntd.0006728. eCollection 2018 Aug.

7.

Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.

Ammerman NC, Swanson RV, Bautista EM, Almeida DV, Saini V, Omansen TF, Guo H, Chang YS, Li SY, Tapley A, Tasneen R, Tyagi S, Betoudji F, Moodley C, Ngcobo B, Pillay L, Bester LA, Singh SD, Chaisson RE, Nuermberger E, Grosset JH.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00636-18. doi: 10.1128/AAC.00636-18. Print 2018 Jul.

8.

Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis.

Xu J, Tasneen R, Peloquin CA, Almeida DV, Li SY, Barnes-Boyle K, Lu Y, Nuermberger E.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01692-17. doi: 10.1128/AAC.01692-17. Print 2018 Jan.

9.

Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.

Park SW, Tasneen R, Converse PJ, Nuermberger EL.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01502-17. doi: 10.1128/AAC.01502-17. Print 2017 Nov.

10.

Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.

Li SY, Tasneen R, Tyagi S, Soni H, Converse PJ, Mdluli K, Nuermberger EL.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00913-17. doi: 10.1128/AAC.00913-17. Print 2017 Sep.

11.

In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.

Kaushik A, Ammerman NC, Tasneen R, Story-Roller E, Dooley KE, Dorman SE, Nuermberger EL, Lamichhane G.

J Antimicrob Chemother. 2017 Aug 1;72(8):2320-2325. doi: 10.1093/jac/dkx152.

12.

In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1.

Gopal P, Tasneen R, Yee M, Lanoix JP, Sarathy J, Rasic G, Li L, Dartois V, Nuermberger E, Dick T.

ACS Infect Dis. 2017 Jul 14;3(7):492-501. doi: 10.1021/acsinfecdis.7b00017. Epub 2017 Mar 16.

13.

Mouse model of pulmonary cavitary tuberculosis and expression of matrix metalloproteinase-9.

Ordonez AA, Tasneen R, Pokkali S, Xu Z, Converse PJ, Klunk MH, Mollura DJ, Nuermberger EL, Jain SK.

Dis Model Mech. 2016 Jul 1;9(7):779-88. doi: 10.1242/dmm.025643. Epub 2016 May 26.

14.

High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis.

Lanoix JP, Tasneen R, O'Brien P, Sarathy J, Safi H, Pinn M, Alland D, Dartois V, Nuermberger E.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4197-205. doi: 10.1128/AAC.03085-15. Print 2016 Jul.

15.

Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.

Tasneen R, Betoudji F, Tyagi S, Li SY, Williams K, Converse PJ, Dartois V, Yang T, Mendel CM, Mdluli KE, Nuermberger EL.

Antimicrob Agents Chemother. 2015 Oct 26;60(1):270-7. doi: 10.1128/AAC.01691-15. Print 2016 Jan.

16.

Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.

Tasneen R, Williams K, Amoabeng O, Minkowski A, Mdluli KE, Upton AM, Nuermberger EL.

Antimicrob Agents Chemother. 2015 Jan;59(1):129-35. doi: 10.1128/AAC.03822-14. Epub 2014 Oct 20.

17.

Reply to "Contradictory results with high-dosage rifamycin in mice and humans".

Nuermberger EL, Rosenthal IM, Tasneen R, Peloquin CA, Mdluli KE, Karakousis PC, Grosset JH.

Antimicrob Agents Chemother. 2013 Feb;57(2):1104-5. doi: 10.1128/AAC.02216-12. No abstract available.

18.

Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.

Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL.

Antimicrob Agents Chemother. 2012 Aug;56(8):4331-40. doi: 10.1128/AAC.00912-12. Epub 2012 Jun 4.

19.

Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions.

Harper J, Skerry C, Davis SL, Tasneen R, Weir M, Kramnik I, Bishai WR, Pomper MG, Nuermberger EL, Jain SK.

J Infect Dis. 2012 Feb 15;205(4):595-602. doi: 10.1093/infdis/jir786. Epub 2011 Dec 23.

20.

Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.

Tasneen R, Li SY, Peloquin CA, Taylor D, Williams KN, Andries K, Mdluli KE, Nuermberger EL.

Antimicrob Agents Chemother. 2011 Dec;55(12):5485-92. doi: 10.1128/AAC.05293-11. Epub 2011 Sep 19.

21.

Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig.

Ahmad Z, Nuermberger EL, Tasneen R, Pinn ML, Williams KN, Peloquin CA, Grosset JH, Karakousis PC.

J Antimicrob Chemother. 2010 Apr;65(4):729-34. doi: 10.1093/jac/dkq007. Epub 2010 Jan 31.

22.

Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.

Almeida D, Nuermberger E, Tasneen R, Rosenthal I, Tyagi S, Williams K, Peloquin C, Grosset J.

Antimicrob Agents Chemother. 2009 Oct;53(10):4178-84. doi: 10.1128/AAC.00830-09. Epub 2009 Jul 20.

23.

Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.

Williams KN, Brickner SJ, Stover CK, Zhu T, Ogden A, Tasneen R, Tyagi S, Grosset JH, Nuermberger EL.

Am J Respir Crit Care Med. 2009 Aug 15;180(4):371-6. doi: 10.1164/rccm.200904-0611OC. Epub 2009 Jun 11.

PMID:
19520903
24.

Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.

Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, Nuermberger E.

Antimicrob Agents Chemother. 2009 Apr;53(4):1314-9. doi: 10.1128/AAC.01182-08. Epub 2008 Dec 15.

25.

Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.

Tasneen R, Tyagi S, Williams K, Grosset J, Nuermberger E.

Antimicrob Agents Chemother. 2008 Oct;52(10):3664-8. doi: 10.1128/AAC.00686-08. Epub 2008 Aug 11.

26.

Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.

Nuermberger E, Tyagi S, Tasneen R, Williams KN, Almeida D, Rosenthal I, Grosset JH.

Antimicrob Agents Chemother. 2008 Apr;52(4):1522-4. doi: 10.1128/AAC.00074-08. Epub 2008 Feb 19.

Supplemental Content

Loading ...
Support Center